Rankings
▼
Calendar
AMRX Q1 2021 Earnings — Amneal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
AMRX
Amneal Pharmaceuticals, Inc.
$4B
Q1 2021 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$493M
-1.1% YoY
Gross Profit
$192M
38.8% margin
Operating Income
$46M
9.3% margin
Net Income
$7M
1.4% margin
EPS (Diluted)
$0.04
QoQ Revenue Growth
-3.3%
Cash Flow
Operating Cash Flow
$148M
Free Cash Flow
$136M
Stock-Based Comp.
$0
Balance Sheet
Total Assets
$4.0B
Total Liabilities
$3.6B
Stockholders' Equity
$323M
Cash & Equivalents
$452M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$493M
$499M
-1.1%
Gross Profit
$192M
$183M
+4.4%
Operating Income
$46M
$58M
-20.6%
Net Income
$7M
$115M
-94.2%
Revenue Segments
Generics Segment
$313M
63%
Amneal Specialty Pharma Segment
$96M
19%
Av K A R E Segment
$85M
17%
← FY 2021
All Quarters
Q2 2021 →